Phase 1 Obesity Trial, Recruiting NCT07514260 Sponsor: AbbVie Condition: Obesity
Back to Obesity

Phase 1 Obesity Trial, Recruiting

NCT07514260
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are Japanese, either first-generation (born in Japan, with both parents and all four grandparents also born in Japan of full Japanese descent) or second-generation (born outside Japan, but with both parents and all four grandparents born in Japan of full Japanese descent).
  • People whose Body Mass Index (BMI) — a number calculated from height and weight — falls between 23.0 and 35.0 at the time of the screening appointment.

Who may not be able to join:

  • People whose body weight has changed by 5% or more in the three months before the screening appointment.
  • People whose blood sugar levels at screening are at or above certain thresholds — specifically, an HbA1c (a measure of average blood sugar over time) of 6.5% or higher, and/or a fasting blood glucose level of 126 mg/dL or higher (confirm with trial site).
  • People who have taken any medication intended to treat obesity — such as GLP-1 agonists, GLP-1/GIP agonists, bupropion-naltrexone, orlistat, metformin, phentermine-topiramate, amphetamine-based stimulants, or methylphenidate — or who have participated in an obesity-related clinical trial within the 180 days before the study treatment begins.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: ABBVIE INC., AbbVie

Phone: 844-663-3742

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Registry
ClinicalTrials.gov
Start date
31 March 2026
Est. completion
1 January 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of Participants with Adverse Events (AEs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov